PT  - JOURNAL ARTICLE
AU  - Brendan T. Bowman
AU  - Benjamin J. Lobo
AU  - Binu Sharma
AU  - Jennie Z. Ma
TI  - Results of an Academic Dialysis Program-Wide SARS-CoV-2 Vaccination Effort
AID  - 10.1101/2021.05.07.21256841
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.05.07.21256841
4099  - http://medrxiv.org/content/early/2021/05/10/2021.05.07.21256841.short
4100  - http://medrxiv.org/content/early/2021/05/10/2021.05.07.21256841.full
AB  - Patients with End Stage Kidney Disease requiring dialysis are exceedingly vulnerable to SARS-CoV-2 infection with high hospitalization rates and mortality. Despite this risk, little is known about real world dialysis patient SARS-CoV-2 vaccination acceptance. Surveys of the general population suggest significant vaccine hesitancy and high potential for refusal. From January 27th to March 12th 2021, the University of Virginia (UVA) Health System, in partnership with the Virginia Department of Health / Blue Ridge Health District (BRHD) provided on-site mobile vaccination clinics at 12 UVA dialysis sites. We conducted a cross-sectional study to evaluate vaccine acceptance and evaluate factors associated with refusal. Of 859 dialysis patients with complete vaccination data, 80% received at least one dose of vaccine and 87% of these vaccinations were provided by the UVA/BRHD partnership. The overall patient refusal rate was low at 14%. Patients refusing SARS-CoV-2 vaccine were more likely to be female, younger and missing a documented flu vaccination during the 2020-2021 season. Attributes such as race or prior infection with SARS-CoV-2 were not significantly associated with vaccine refusal. In conclusion, dialysis patients in our program were surprisingly likely to accept vaccination for SARS-CoV-2. Identifying attributes associated with refusal may help target populations at high risk of vaccine refusal.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding supported this workAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The research proposal was evaluated by the UVA Institutional Review Board for Health Sciences Research and found to be exempt from IRB review / not human subjects research (tracking #23147)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is not freely available externally. Please contact author if interested in de-identified data set for research purposes